Keratitis due to Aspergillus flavus: clinical profile, molecular identification of fungal strains and detection of aflatoxin production.
OBJECTIVE
To document the clinical profile of patients with keratitis due to Aspergillus flavus and to elaborate on differences in the aflatoxin-producing potential of keratitis strains versus environmental strains of A. flavus.


METHODS
Over a 6-month period, strains of Aspergillus flavus were isolated in culture from corneal scrape or biopsy material of patients who presented with suppurative keratitis (clinical isolates). The strains were confirmed to be A. flavus by molecular methods (amplification of the internal transcribed spacer 2 [ITS 2] region and direct sequencing followed by comparative GenBank analysis). The aflatoxin-producing potential of each strain was determined by thin-layer chromatography. The ability of each strain to form sclerotia in Czapek-Dox agar (CDA) after 7 days incubation at 30 degrees C in the dark and to produce a beige ring in yeast extract sucrose agar supplemented with methyl beta-cyclodextrin and sodium desoxycholate (YESD medium) after 3 days incubation at 30 degrees C was also assessed. For comparison, the tests were also run on 10 strains of A. flavus (identity confirmed by molecular methods) collected from local farming areas (environmental isolates).


RESULTS
Aflatoxin B1 was detected in 16 (80%) of 20 culture filtrate or mycelial homogenate samples of the clinical isolates (mean concentration: 366.7+/-125.4 parts per billion [ppb]) but in only eight (40%) of 20 samples of environmental isolates (mean concentration: 306.6+/-125.4 ppb). Seven of the eight aflatoxin-producing clinical isolates and two of the four aflatoxin-producing environmental isolates formed sclerotia (>400 microm) and a beige ring in culture.


CONCLUSIONS
Aflatoxin B1 was detected in a significantly higher percentage of growth samples of clinical isolates (80%) than growth samples of environmental isolates (40%) (chi(2)=6.667; p=0.0098); the therapeutic implications of this finding require further study. The production of sclerotia and a beige ring in culture appear to be useful markers of aflatoxin-producing potential in strains of A. flavus isolated from keratitis.
Leema
George
G
Department of Animal Science, School of Life Sciences, Bharathidasan University, Tamil Nadu, India.
Kaliamurthy
Jayaraman
J
Geraldine
Pitchairaj
P
Thomas
Philip A
PA
D000328:Adult; D016604:Aflatoxin B1 / Q000096:biosynthesis; D000348:Aflatoxins / Q000096:biosynthesis*; D000368:Aged; D001228:Aspergillosis; D001231:Aspergillus flavus / Q000145:classification* / Q000302:isolation & purification / Q000378:metabolism*; D004783:Environmental Microbiology; D005260:Female; D006801:Humans; D007634:Keratitis / Q000382:microbiology*; D008297:Male; D008875:Middle Aged; D013045:Species Specificity
D000348:Aflatoxins; D016604:Aflatoxin B1
Food Chem Toxicol. 1988 Jul;26(7):579-86
3141255
Br J Ophthalmol. 1996 Jan;80(1):29-32
8664227
Acta Pharmacol Toxicol (Copenh). 1978 Oct;43(4):273-9
716944
Infect Immun. 1984 Jan;43(1):320-5
6360904
Mycologia. 1979 Mar-Apr;71(2):415-22
114828
J Clin Microbiol. 2005 May;43(5):2092-103
15872227
Curr Genet. 1996 May;29(6):549-55
8662194
Mycopathologia. 1988 Apr;102(1):9-12
3138542
Med Mycol. 2002 Feb;40(1):87-109
11860017
Appl Environ Microbiol. 1998 Oct;64(10):3713-7
9758789
Indian J Ophthalmol. 1984 Sep-Oct;32(5):424-6
6443611
Med Mycol. 1998 Apr;36(2):107-12
9776821
Med Mycol. 2005 May;43 Suppl 1:S87-93
16110798
Annu Rev Pharmacol Toxicol. 1994;34:135-72
8042848
J Assoc Off Anal Chem. 1975 Jan;58(1):163-4
1141149
Morphol Embryol (Bucur). 1980 Oct-Dec;26(4):309-14
6450879
Carcinogenesis. 1994 May;15(5):947-55
8200100
Eur Neuropsychopharmacol. 2003 Jan;13(1):49-52
12480122
Mycoses. 2009 May;52(3):206-22
19207851
Acta Pharm. 2005 Dec;55(4):365-75
16375826
J Clin Microbiol. 2000 Apr;38(4):1510-5
10747135
Doc Ophthalmol. 1992;79(3):269-76
1600844
Eye (Lond). 2003 Nov;17(8):852-62
14631389
Appl Environ Microbiol. 1997 Mar;63(3):1048-53
16535539
Am J Ophthalmol. 2008 Aug;146(2):260-265
18547535
Br J Ophthalmol. 2005 Dec;89(12):1554-8
16299128
Appl Microbiol Biotechnol. 2003 Apr;61(2):83-93
12655449
Mycologia. 1974 Mar-Apr;66(2):365-9
4208153
Microbiol Immunol. 2003;47(9):631-8
14584610
Microbiol Mol Biol Rev. 2002 Sep;66(3):447-59, table of contents
12208999
Phytopathology. 1997 Jun;87(6):643-8
18945083
Pharmacol Toxicol. 1992 Oct;71(4):262-71
1454751
J Clin Microbiol. 2009 Oct;47(10):3138-41
19675215
Clin Microbiol Rev. 2003 Jul;16(3):497-516
12857779
Appl Microbiol. 1974 Mar;27(3):452-6
4824880
Med Mycol. 2005 May;43 Suppl 1:S49-58
16110792
Microbiology (Reading). 2007 Jun;153(Pt 6):1677-1692
17526826
Adv Appl Microbiol. 1983;29:53-92
6650265
Clin Infect Dis. 1998 Apr;26(4):781-803; quiz 804-5
9564455
J Anim Sci. 1996 Jul;74(7):1672-80
8818814
Int J Food Microbiol. 2003 Jun 15;83(2):219-25
12706042
Appl Microbiol. 1975 Dec;30(6):1050-1
2104
Clin Microbiol Rev. 1996 Oct;9(4):469-88
8894347
Indian J Med Sci. 2004 Dec;58(12):513-9
15627677
J Toxicol Environ Health B Crit Rev. 2000 Apr-Jun;3(2):109-43
10834078
Am J Ophthalmol. 2005 Nov;140(5):851-857
16310463
J Clin Microbiol. 1997 Jun;35(6):1454-9
9163461
J Basic Microbiol. 1987;27(9):511-4
3136240